Affimed Logo
  • Science and Technology
    • ICE® (innate cell engager) Molecules
    • ROCK® Platform
    • Publications and Posters
  • Pipeline and Clinical Trials
  • About Us
    • Management Board
    • Supervisory Board
    • Scientific Advisory Board
    • Partners
  • News and Events
  • Innately Affimed
  • Investors
    • Webcasts and Corporate Presentation
    • Analyst Coverage
    • Share Information
    • SEC and Financial Reports
    • Corporate Governance Affimed
    • Press Release Distribution
  • Careers
    • Culture
  • Contact
Menu

News and Events

See what’s new at Affimed

News

All categories
Earnings
Press Release
All years
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Affimed Announces Collaboration with Roche to Study AFM24 in Combination with PD-L1 Checkpoint Inhibitor in EGFR Expressing Solid Tumors

February 3, 2021

Affimed Announces Closing of Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares

January 15, 2021

Affimed Announces Pricing of $100,000,000 Public Offering of Common Shares

January 13, 2021

Affimed Announces Proposed Public Offering of Common Shares

January 12, 2021

Affimed to Present at the 39th Annual J.P. Morgan Healthcare Conference

January 11, 2021

Affimed Announces €25 Million Debt Financing Agreement with Silicon Valley Bank

January 11, 2021

Affimed Announces Pipeline and Business Update

January 7, 2021

Affimed Announces Updated AFM13 Clinical Data Presentation at the American Society of Hematology Annual Meeting, Demonstrating Good Tolerability and a High Objective Response Rate in Patients with Recurrent/Refractory CD30-positive Lymphoma with Cutaneous Presentation

December 7, 2020

Affimed Announces Publication of Final Study Results of its Innate Cell Engager Candidate AFM13 in Combination with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in Blood

November 19, 2020

Affimed Reports Third Quarter 2020 Financial Results and Highlights Recent Operational Progress

November 10, 2020

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27

Events

All
Scientific
Investors

28Mar

Innate Killer Summit

March 28 - 30, 2023 (San Diego, USA)

WebcastsMore events

Affimed GmbH
Technologiepark
Im Neuenheimer Feld 582
69120 Heidelberg, Germany

Phone: +49 (0)6221-6743-60
Fax: +49 (0)6221 6743-649
email hidden; JavaScript is required

  • Affimed Science and Technology
    • ICE® (innate cell engager) Molecules
    • ROCK® Platform
    • Publications and Posters
  • About Us
    • Management Board
    • Supervisory Board
    • Scientific Advisory Board
    • Partners
  • News and Events
  • Investors
    • Webcasts and Corporate Presentation
    • Analyst Coverage
    • Share Information
    • SEC and Financial Reports
    • Press Release Distribution
    • Corporate Governance
  • Careers
    • Culture

© 2023 Affimed GmbH

  • Data Protection
  • Imprint
  • Contact